http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. A new therapeutic approach to diabetes that combines insulin and an inhibitor of the epidermal growth factor (EGF) betacellulin could limit the progression of diabetic macular edema (DME), Cleveland Clinic researcher Bela Anand-Apte, MD, PhD, said at the American Society for Cell Biology Annual Meeting, on Dec. 17 in San Francisco. http://medicalxpress.com/news/2012-12-insulin-growth-factor-inhibitor-limits.html Diabetes Mon, 17 Dec 2012 18:00:01 EST news274986876 (HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according to research published online Oct. 8 in the Archives of Ophthalmology. http://medicalxpress.com/news/2012-10-long-term-ranibizumab-beneficial-macular-edema.html Ophthalmology Thu, 11 Oct 2012 18:30:01 EST news269194573 The U.S. Food and Drug Administration today announced its approval of Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, or DME, an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness. A retinal specialist at The Methodist Hospital in Houston, Texas, was one of the lead investigators in the research that led to today’s FDA approval. http://medicalxpress.com/news/2012-08-fda-drug-diabetic-macular-edema.html Medications Mon, 13 Aug 2012 09:12:06 EST news264067919 Treatment with glucose-lowering thiazolidinedione drugs in patients with Type 2 diabetes appears to be associated with an increased risk of diabetic macular edema (a complication that may affect vision) at 1-year and 10-year follow-up evaluations, according to a report published Online First by Archives of Internal Medicine. http://medicalxpress.com/news/2012-06-thiazolidinedione-patients-diabetes-diabetic-macular.html Diabetes Mon, 11 Jun 2012 16:01:45 EST news258649293 A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that was previously demonstrated at 12 months was maintained through 24 months, according to a report published Online First by Archives of Ophthalmology. http://medicalxpress.com/news/2012-04-two-year-outcomes-diabetic-macular-edema.html Ophthalmology Mon, 09 Apr 2012 16:00:02 EST news253189745